Novo Nordisk Accelerates Drug Development with AI-Powered Clinical Documentation Platform
About
Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, implemented NovoScribe—an AI-powered documentation platform built with Claude models on Amazon Bedrock—to transform clinical study report production from a months-long manual process into an automated system that generates regulatory-grade content in minutes.
The Challenge
What went wrong
Clinical study reports can run up to 300 pages, and staff writers averaged only 2.3 reports per year due to the grueling multi-month cycle of writing, reviews, rewrites, and approvals. Each day of delay in bringing a new medicine to market costs up to $15 million in potential revenue, while patients with chronic conditions continue waiting for life-transforming treatments. Claude Early AI models tested by Novo Nordisk, including ChatGPT and Llama, often made so many errors that fixing them took longer than rewriting from scratch.
Solution Approach
How it was solved
Novo Nordisk built NovoScribe using Claude Code and MongoDB Atlas, combining retrieval-augmented generation with domain expert-approved text and case-specific variables to produce accurate, compliant documentation. Claude After benchmarking AI providers on clinical data accuracy, Novo Nordisk chose Claude models deployed securely via Amazon Bedrock, with the platform consistently earning positive feedback from regulators.
Results Achieved
Success Metrics
Documentation writing time was reduced by 90%, with clinical study reports that previously took 10-15 weeks now completed in 10 minutes. Review-to-approval cycles decreased by 50% as reviewers became increasingly satisfied with clinical interpretation and output quality. ClaudeMongoDB Device verification protocols that previously required entire departments now need just one user. For new trials, complete study booklets and patient guides are produced in under a minute—materials that previously required months of back-and-forth work with external agencies. Anthropic The team scaled from requiring 50 writers to just 3, with annual Claude costs less than a single writer's salary.
Verified Testimonials
Real voices from people who witnessed this story firsthand
Jim Kong
👔 Drug R&D Manager
🏢 Novo Nordisk
Novo Nordisk, the pharmaceutical giant behind Ozempic and Wegovy, implemented NovoScribe—an AI-powered documentation platform built with Claude models on Amazon Bedrock—to transform clinical study report production from a months-long manual process into an automated system that generates regulatory-grade content in minutes.
Kupper
👔 Director of Drug Research and Development
🏢 Novo Nordisk
Documentation writing time was reduced by 90%, with clinical study reports that previously took 10-15 weeks now completed in 10 minutes. Review-to-approval cycles decreased by 50% as reviewers became increasingly satisfied with clinical interpretation and output quality. ClaudeMongoDB Device verification protocols that previously required entire departments now need just one user.
Want to learn more about this success story?
Discover the full story and explore more about how this challenge was overcome